This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Clinic Radiation Radiopharmaceuticals 
AuntMinnie
MAY 8, 2024
Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. It causes radiation injury that may be visible as dry desquamation or moist desquamation, for example.
AuntMinnie
SEPTEMBER 30, 2024
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JULY 12, 2024
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Underwood led the nuclear medicine and radiopharmaceutical therapy team within radiation safety at Mayo Clinic and directly supports the program in Rochester.
264 
AuntMinnie
FEBRUARY 26, 2025
The analysis might help to establish a model for balancing clinical and environmental priorities in radiology departments globally. Late-phase imaging was performed when clinically indicated for liver or kidney conditions. SPECT and low-dose CT scans could be added for areas with suspected radiopharmaceutical uptake.
130 
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
264 
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
306 
AuntMinnie
OCTOBER 25, 2024
Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. One of this year's nominations for Most Influential Radiology Researcher is Erik Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL.
358 
Imaging Technology
JANUARY 5, 2024
announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.
AuntMinnie
FEBRUARY 24, 2025
An open-source AI tool can help predict renal function decline in prostate cancer patients undergoing lutetium-177 (Lu-177) radiopharmaceutical therapy, according to a study published February 25 in Radiology.
AuntMinnie
MARCH 25, 2024
PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. The game-changer could be the pending U.S. approval of new PET radiotracers, such as F-18 flurpiridaz , he said.
321 
AuntMinnie
JUNE 20, 2024
MIBI-SPECT/CT is considered the standard technique for guiding these surgeries, yet several phase II clinical trials suggest advantages of a newer approach using FCH-PET, such as superior spatial resolution for detecting small adenomas and lower radiation exposure to patients, they noted. The full study is available here.
Imaging Technology
MAY 23, 2023
milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C.
Imaging Technology
SEPTEMBER 20, 2023
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
105 
AuntMinnie
OCTOBER 2, 2024
Assessment of Claimant, Clinical, and Financial Characteristics of Teleradiology Medical Malpractice Cases. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. Neuroimaging and Clinical Findings in Healthy Middle-Aged Adults With Mild Traumatic Brain Injury in the PREVENT Dementia Study.
AuntMinnie
APRIL 4, 2024
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.
222 
Imaging Technology
JULY 25, 2023
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
AuntMinnie
NOVEMBER 4, 2024
reduction in average Medicare payment rates compared with 2024, the CMS has estimated there will be a 0% change to reimbursement for radiology, nuclear medicine, and radiation oncology. The American Society for Radiation Oncology (ASTRO) was disappointed in the final MPFS rule. Although the 2025 MPFS calls for an overall 2.9%
Imaging Technology
JUNE 29, 2023
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.
98 
Imaging Technology
JULY 20, 2023
milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.
AuntMinnie
JANUARY 11, 2024
These are created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that targets the cancer itself. The first code, C9794, defines a separate pre-treatment procedure in which radiopharmaceutical emissions data is collected for use in creating the treatment delivery plan.
Imaging Technology
JULY 11, 2023
We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.
Imaging Technology
AUGUST 29, 2023
Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
Imaging Technology
NOVEMBER 1, 2024
Radiation dosimetry performed for up to three cycles showed delivery of high tumor absorbed radiation doses relative to the dose delivered to the key normal organs, such as kidney and salivary glands. In combination with the positive radiation dosimetry results seen in Phase 1 for Lutetium ( 177 Lu) rhPSMA-10.1
Imaging Technology
NOVEMBER 26, 2023
TeleDaaS specializes in delivering clinical-grade, precision-based dosimetry analysis and treatment plans to clinical research organizations (CROs) and pharmaceutical manufacturers. Radiopharmaceuticals are revolutionizing modern cancer treatment and precision dosimetry is a crucial component of this advanced therapy.
78 
AuntMinnie
JUNE 14, 2024
The proposed extravasation rule avoids having a minimum dose threshold; "instead, it's worded in a way that it would have to result in a radiation injury." Flannery responded that the focus is on radiation injury, retrospectively, and that has to be determined by an authorized user physician.
130 
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
130 
Imaging Technology
AUGUST 31, 2023
milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We
98 
Imaging Technology
APRIL 5, 2024
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
Imaging Technology
JULY 28, 2023
We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We
98 
Imaging Technology
AUGUST 30, 2023
The study was published in the International Journal of Radiation Oncology, Biology, Physics. FLASH is an experimental mode of delivering radiation therapy for cancer that can be delivered to a patient in less than one second and which can be over 100 times faster than conventional radiation therapy.
Imaging Technology
JULY 5, 2023
Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.
92 
Imaging Technology
JANUARY 12, 2024
“We are grateful that CMS recognizes the potential of our SCINTIX therapy for patients with all stages of indicated cancers and, with this decision, has addressed provider payment as a barrier to clinical adoption,” continued Powell. Patient treatments also began at several clinical sites in 2023. 1, 2024, to describe SCINTIX therapy.
Imaging Technology
APRIL 3, 2023
Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.
98 
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.
98 
Imaging Technology
AUGUST 23, 2023
SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion. “We founder and CTO of RefleXion.“We
Imaging Technology
OCTOBER 18, 2023
About Targeted Alpha Therapy Targeted Alpha Therapy is an emerging class of cancer therapeutics, which seeks to deliver alpha radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g.,
Imaging Technology
MAY 14, 2024
milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. This alliance will help UH expand patient access and transform cancer care from discovery to recovery.
116 
Imaging Technology
SEPTEMBER 27, 2023
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,
105 
Imaging Technology
APRIL 2, 2024
As patient procedures grow in number and complexity throughout a variety of care areas, today’s staffing shortages and other clinical challenges are expected to become more significant. There is also special focus on radiation therapy and Theranostics.
105 
Imaging Technology
JULY 21, 2023
Several of these presentations detail our successfully completed clinical study that supported our FDA clearance for SCINTIX therapy, while others explore its breakthrough potential in treating multiple moving tumors.” will share their clinical experience with the X1 and how they are preparing for SCINTIX therapy. Chunhui Han , Ph.D.,
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.
97 
Imaging Technology
OCTOBER 4, 2024
Specifically, the purpose of dosimetry in radiotherapy is to estimate the amount of dose that will be absorbed by normal tissues and tumors to anticipate the biologic effects of radiation. Traditionally, the Monte Carlo technique has been considered too slow for clinical use, taking up to several hours or more to complete calculations.
TTG Imaging Solutions
MAY 5, 2023
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA.
52 
Imaging Technology
OCTOBER 5, 2023
Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Gauden, D.Phil.
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content